Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pseudomyxoma Peritonei × Alemtuzumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 37 Leukemia 35 Lymphoma 27 Myelodysplastic Syndromes 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Lymphoma, Non-Hodgkin 16 Hodgkin Disease 15 Leukemia, Myeloid, Acute 14 Myeloproliferative Disorders 13 Multiple Myeloma 13 Lymphoma, Follicular 9 Lymphoma, Mantle-Cell 8 Lymphoma, Large B-Cell, Diffuse 8 Leukemia, Myeloid, Chronic-Phase 8 Hematologic Neoplasms 8 Anemia, Aplastic 8 Neoplasms, Plasma Cell 7 Lymphoma, B-Cell, Marginal Zone 7 Congenital Abnormalities 7 Burkitt Lymphoma 7 Recurrence 6 Primary Myelofibrosis 6 Lymphoma, T-Cell, Peripheral 6 Lymphoma, Large-Cell, Immunoblastic 6 Leukemia, Myelomonocytic, Chronic 6 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6 Waldenstrom Macroglobulinemia 5 Sezary Syndrome 5 Myelodysplastic-Myeloproliferative Diseases 5 Mycosis Fungoides 5

Interventions

Mitomycin 3 Hyperthermic Intraperitoneal Chemotherapy 3 Fluorouracil 2 Capecitabine 2 tislelizumab 1 molgramostim 1 irinotecan sucrosofate 1 Tacrolimus 1 Surveys and Questionnaires 1 Sirolimus 1 Radiosurgery 1 Psychiatric Rehabilitation 1 Pharmacogenomic Testing 1 Oxaliplatin 1 Observation 1 Methods 1 Leucovorin 1 Lansoprazole 1 Ifosfamide 1 Gemcitabine 1 Early Intervention, Educational 1 Doxorubicin 1 Cytoreduction Surgical Procedures 1 Clarithromycin 1 Cisplatin 1 Carboplatin 1 Behavior Therapy 1 Amoxicillin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡